1. Short-chain fatty acid valerate reduces voluntary alcohol intake in male mice
- Author
-
Suresh C. Bokoliya, Jordan Russell, Yair Dorsett, Hunter A. Panier, Vijender Singh, Lauren Daddi, Hanshu Yuan, Liv R. Dedon, Zhongmao Liu, Yuqi Zhou, Zefang Min, Jessica R. Barson, Jonathan Covault, Jason A. Bubier, and Yanjiao Zhou
- Subjects
Alcohol drinking ,SCFA ,Sodium valerate ,GABA ,Microbiome ,Microbial ecology ,QR100-130 - Abstract
Abstract Background Despite serious health and social consequences, effective intervention strategies for habitual alcohol binge drinking are lacking. The development of novel therapeutic and preventative approaches is highly desirable. Accumulating evidence in the past several years has established associations between the gut microbiome and microbial metabolites with drinking behavior, but druggable targets and their underlying mechanism of action are understudied. Results Here, using a drink-in-the-dark mouse model, we identified a microbiome metabolite-based novel treatment (sodium valerate) that can reduce excessive alcohol drinking. Sodium valerate is a sodium salt of valeric acid short-chain fatty acid with a similar structure as γ-aminobutyric acid (GABA). Ten days of oral sodium valerate supplementation attenuates excessive alcohol drinking by 40%, reduces blood ethanol concentration by 53%, and improves anxiety-like or approach-avoidance behavior in male mice, without affecting overall food and water intake. Mechanistically, sodium valerate supplementation increases GABA levels across stool, blood, and amygdala. It also significantly increases H4 acetylation in the amygdala of mice. Transcriptomics analysis of the amygdala revealed that sodium valerate supplementation led to changes in gene expression associated with functional pathways including potassium voltage-gated channels, inflammation, glutamate degradation, L-DOPA degradation, and psychological behaviors. 16S microbiome profiling showed that sodium valerate supplementation shifts the gut microbiome composition and decreases microbiome-derived neuroactive compounds through GABA degradation in the gut microbiome. Conclusion Our findings suggest that sodium valerate holds promise as an innovative therapeutic avenue for the reduction of habitual binge drinking, potentially through multifaceted mechanisms. Video Abstract
- Published
- 2024
- Full Text
- View/download PDF